PF-Atlas › Clinical Trials › NCT02532764
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
QR-010 · Phase 1
Registry ID
NCT02532764
Phase
Phase 1
Status
Completed
Drug / intervention
QR-010
Sponsor
ProQR Therapeutics
Start
2015-06
Enrollment
70
Locations
27
About this trial
A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02532764 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.